NEW YORK (GenomeWeb News) – DxS today said that it has expanded its licensing deal with Genzyme Genetics covering the epidermal growth factor receptor gene.
 
The license gives Manchester, UK-based DxS rights to develop and sell diagnostic and research products that detect mutations in the EGFR gene for non-small cell lung cancer in the US and Canada. The deal builds on an agreement inked earlier this year that gave DxS similar rights to EGFR worldwide, except for North America and Hong Kong.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.